Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fampridine on Working Memory in Healthy Subjects
NCT04516603Phase 2Withdrawn
- Start
- Jan 2040
- Primary completion
- Dec 2041
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dalfampridine in cognitive impairment. Planned start Jan 2040; status: withdrawn.
02
Drugs
dalfampridine
03
Conditions
cognitive impairment
Beyond the preview
Go deeper on NCT04516603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04516603.